Fiera Capital Corp Has $4.352 Million Stake in Celgene Co. (CELG)

Fiera Capital Corp cut its position in shares of Celgene Co. (NASDAQ:CELG) by 19.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,593 shares of the biopharmaceutical company’s stock after selling 9,050 shares during the period. Fiera Capital Corp’s holdings in Celgene were worth $4,352,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CELG. Jennison Associates LLC increased its stake in Celgene by 14.1% in the third quarter. Jennison Associates LLC now owns 15,921,002 shares of the biopharmaceutical company’s stock worth $1,664,222,000 after buying an additional 1,967,645 shares during the last quarter. Two Sigma Advisers LP increased its stake in Celgene by 1,980.8% in the third quarter. Two Sigma Advisers LP now owns 1,778,808 shares of the biopharmaceutical company’s stock worth $185,939,000 after buying an additional 1,693,322 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Celgene by 19.9% in the third quarter. Bank of New York Mellon Corp now owns 9,460,931 shares of the biopharmaceutical company’s stock worth $988,951,000 after buying an additional 1,567,515 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in Celgene during the third quarter worth $162,049,000. Finally, Asset Management One Co. Ltd. increased its stake in Celgene by 363.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 1,354,324 shares of the biopharmaceutical company’s stock worth $156,883,000 after buying an additional 1,062,067 shares during the last quarter. 77.68% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Celgene Co. (NASDAQ:CELG) traded down 0.82% on Friday, hitting $122.26. The stock had a trading volume of 2,906,232 shares. The company has a market cap of $95.11 billion, a P/E ratio of 49.10 and a beta of 1.74. Celgene Co. has a 1-year low of $94.42 and a 1-year high of $127.64. The stock has a 50 day moving average price of $124.35 and a 200 day moving average price of $116.33.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, January 26th. The biopharmaceutical company reported $1.61 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.59 by $0.02. The company earned $2.98 billion during the quarter, compared to the consensus estimate of $3.03 billion. Celgene had a net margin of 17.80% and a return on equity of 77.95%. The firm’s quarterly revenue was up 16.3% on a year-over-year basis. During the same period in the previous year, the firm posted $1.18 earnings per share. On average, equities research analysts expect that Celgene Co. will post $7.23 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was posted by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://baseballnewssource.com/markets/fiera-capital-corp-sells-9050-shares-of-celgene-co-celg-updated-updated/525828.html.

Several analysts recently weighed in on the company. Leerink Swann restated a “market perform” rating on shares of Celgene in a research report on Monday, March 20th. Jefferies Group LLC restated a “buy” rating and set a $154.00 price objective on shares of Celgene in a research report on Tuesday, April 11th. Oppenheimer Holdings Inc. restated an “outperform” rating and set a $148.00 price objective on shares of Celgene in a research report on Wednesday, April 5th. Cann restated a “buy” rating and set a $148.00 price objective on shares of Celgene in a research report on Tuesday, April 4th. Finally, Zacks Investment Research downgraded Celgene from a “buy” rating to a “hold” rating in a research report on Thursday, March 9th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-four have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $139.46.

In other Celgene news, Director Gilla Kaplan sold 14,033 shares of the company’s stock in a transaction dated Thursday, March 30th. The shares were sold at an average price of $123.83, for a total value of $1,737,706.39. Following the completion of the transaction, the director now owns 73,109 shares in the company, valued at $9,053,087.47. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Rupert Vessey sold 4,000 shares of the company’s stock in a transaction dated Wednesday, March 1st. The stock was sold at an average price of $124.42, for a total transaction of $497,680.00. Following the completion of the transaction, the insider now owns 778 shares of the company’s stock, valued at approximately $96,798.76. The disclosure for this sale can be found here. Insiders own 0.97% of the company’s stock.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Ratings for Celgene Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Co. and related companies with our FREE daily email newsletter.

 


Latest News

Gift Ngoepe Becomes First African to Play in MLB
Gift Ngoepe Becomes First African to Play in MLB
Eric Thames Pulled From Game With Tightness in Hamstring
Eric Thames Pulled From Game With Tightness in Hamstring
Julio Urias Returning to Dodgers Thursday
Julio Urias Returning to Dodgers Thursday
Tony Gwynn Jr. Like Father Like Son in Baseball and Brewing
Tony Gwynn Jr. Like Father Like Son in Baseball and Brewing
Sources Say Luis Robert Will Be Cleared by May 20 to Sign
Sources Say Luis Robert Will Be Cleared by May 20 to Sign
Colorado Rockies Bullpen Helping Them to NL West Lead
Colorado Rockies Bullpen Helping Them to NL West Lead


Leave a Reply

 
© 2006-2017 BBNS.